St. Jude Reference #SJ-19-0024
Researchers at St. Jude have invented a cell therapy that consists of tumor-specific T cells in which DMNT3a is knocked out and the STAT5 pathway is activated by IL15. This is useful in developing immunotherapies for cancer and other diseases targeting defined antigens (pediatrics as well as adult). The researcher’s results indicate effector function was dramatically improved and development continues.
T cell therapy, solid tumor, DMNT3 knockout, STAT5 pathway, IL15
Granted patents or published applications
Pending US application and international application published as WO 2020/210365 A1
Related scientific references
Brooke Prinzing et al, Deleting DNMT3A in CAR T cells prevents exhaustion and enhances antitumor activity, Science Translational Medicine (2021). DOI: 10.1126/scitranslmed.abh0272
St. Jude is seeking a partner or partners to help develop this for use with therapies.
Contact the Office of Technology Licensing (Phone: 901-595-2342, Fax: 901-595-3148) for more information.